PAVmed Inc
NASDAQ:PAVM
PAVmed Inc
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
Balance Sheet Progress: PAVmed has made significant headway in restructuring its balance sheet and corporate structure, including a major debt restructuring and deconsolidation of Lucid Diagnostics.
Lucid Diagnostics Update: Lucid remains PAVmed’s main asset, secured a successful $27 million capital raise, and is close to obtaining Medicare coverage for EsoGuard after positive contractor endorsement.
Veris Advances: Veris, the digital health subsidiary, restarted implantable device development with new funding, aiming for FDA submission in 2026, and launched a commercial partnership with OSU targeting 1,000 patients.
Expanding Portfolio: PAVmed is moving to add a new endoscopic imaging technology from Duke/UNC via an imminent licensing agreement, broadening its innovation pipeline.
Financials: Reported GAAP net loss of $6 million for the quarter and a non-GAAP loss of $446,000, with stable operating expenses averaging $4.4 million over the last four quarters.
Outlook: Management expects PAVmed to return to its vision as a diversified life sciences company, with near-term steps to further strengthen its financial position and support growth in current and new subsidiaries.
